Bloomberg News

Boehringer Ingelheim Says NICE Issues Pradaxa Recommendation

November 02, 2011

Nov. 2 (Bloomberg) -- Boehringer Ingelheim said the National Institute for Health and Clinical Excellence in the United Kingdom has issued a Final Appraisal Determination recommending its Pradaxa oral anticoagulant as a treatment option, the company said in an e-mailed statement today. The licensed indication is for the prevention of stroke and systemic embolism in people with non-valvular atrial fibrillation with one or more risk factors and the institute’s recommendation is without any restrictions within the indication.

To contact the editor responsible for this story: Mariajose Vera at

Steve Ballmer, Power Forward
blog comments powered by Disqus